Kura Oncology and Kyowa Kirin Forge Global Partnership to Develop and Commercialize Ziftomenib for Acute Myeloid Leukemia

Metropolis Healthcare's Landmark Study Highlights the Role of Molecular Profiling in Advancing Lung Cancer Care

Novartis Acquires Kate Therapeutics for $1.1 Billion to Advance Gene Therapies for Neuromuscular Diseases

OneCell Diagnostics Secures $16M to Revolutionize Cancer Diagnostics

FDA Grants Accelerated Approval to Ziihera® (zanidatamab-hrii) for HER2-Positive Biliary Tract Cancer

Illumina Unveils TruSight™ Oncology 500 v2 for Comprehensive Genomic Profiling

Tagomics Partners with Agilent Technologies to Revolutionize Multiomic Biomarker Discovery

Bio-Techne Partners with Leader Life Sciences to Expand in the GCC Region

Owkin and Proscia Partner to Revolutionize MSI Testing for Colorectal Cancer with AI-Powered Solutions

Telix Expands Theranostic Pipeline with FAP-Targeting Radiopharmaceuticals

Alamar Biosciences and The Michael J. Fox Foundation Partner to Advance Parkinson’s Disease Biomarker Discovery

Stilla Technologies Partners with Source BioScience to Advance Genomics in the UK and Ireland

Quell Therapeutics and AstraZeneca Advance CAR-Treg Therapy for Type 1 Diabetes

AbbVie’s ELAHERE® Approved in the EU for Platinum-Resistant Ovarian Cancer

AstraZeneca’s Tagrisso Recommended for Approval in EU for Unresectable EGFR-Mutated NSCLC

Home
/
update
/
details

Metropolis Healthcare's Landmark Study Highlights the Role of Molecular Profiling in Advancing Lung Cancer Care

NextEdge Admin

23 Nov 2024

2 min 31 sec

lung cancer,targeted therapies,gene panels

Metropolis Healthcare conducted a landmark seven-year study (2015-2021) analyzing the clinicopathological and molecular features of over 3,200 lung cancer patients. The study focused on genetic alterations in key genes like Epidermal Growth Factor Receptor (EGFR), Anaplastic Lymphoma Kinase (ALK), and c-ros oncogene 1 (ROS1), which are pivotal in non-small cell lung cancer (NSCLC) development. Molecular profiling of these markers is revolutionizing cancer care by enabling targeted therapies tailored to patients’ genetic profiles.

The study highlighted next-generation sequencing (NGS) as a critical tool for identifying lung cancer cases and uncovering actionable molecular targets, leading to expanded treatment options. Among the analyzed samples, 83% were adenocarcinomas (a common NSCLC type), while 17% were squamous cell carcinomas, primarily seen in patients over 60. The findings emphasized the importance of molecular diagnostics in guiding personalized treatment strategies.

Dr. Kirti Chadha, chief scientific and innovation officer at Metropolis Healthcare, stressed the value of genetic profiling in selecting the most effective treatments. "Detailed molecular analysis enables clinicians to tailor therapies to a patient’s genetic profile, significantly improving treatment outcomes in NSCLC care,” she noted.

The study aligns with evolving global standards in molecular diagnostics, such as the 2023 ESMO guidelines, which recommend a broader range of biomarkers, including BRAF, RET, MET, NTRK, HER2, and KRAS G12C. These advances build on the 2017 NCCN guidelines, which emphasized ALK, ROS1, and EGFR mutations. By incorporating comprehensive 50-gene panels, Metropolis Healthcare is expanding its mutation detection capabilities, reinforcing its commitment to precision medicine and improving lung cancer outcomes through advanced molecular profiling.